A US Food and Drug Administration (FDA) panel will meet next month to decide on two new uses of Roche’s cancer drug Avastin, it has been announced.
The company wants approval for the drug to be used as a first-choice treatment for patients with metastatic HER2-negative breast cancer in combination with the chemotherapy product docetaxel.
Regulators will also consider whether to permit use of Avastin in certain breast cancer patients who have not received chemotherapy.
The drug, Roche’s biggest product, is already approved for treating other types of cancer.
Previous research has shown that the drug, when used as a first-choice option, extended the time patients lived without their cancer growing.
The group will meet on July 20.
Copyright Press Association 2010
Food and Drug Administration